DK1409006T3 - Monodispergerede blandinger og fremgangsmåder til behandling af diabetes - Google Patents

Monodispergerede blandinger og fremgangsmåder til behandling af diabetes

Info

Publication number
DK1409006T3
DK1409006T3 DK02709541.3T DK02709541T DK1409006T3 DK 1409006 T3 DK1409006 T3 DK 1409006T3 DK 02709541 T DK02709541 T DK 02709541T DK 1409006 T3 DK1409006 T3 DK 1409006T3
Authority
DK
Denmark
Prior art keywords
methods
patient
diabetes mellitus
treatment
diabetes
Prior art date
Application number
DK02709541.3T
Other languages
English (en)
Inventor
Nnochiri N Ekwuribe
Christopher H Price
James Gordon Still
Jennifer Ann Filbey
Balasingam Radhakrishnan
Amy L Odenbaugh
Aslam M Ansari
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Application granted granted Critical
Publication of DK1409006T3 publication Critical patent/DK1409006T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK02709541.3T 2001-02-15 2002-02-14 Monodispergerede blandinger og fremgangsmåder til behandling af diabetes DK1409006T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26919801P 2001-02-15 2001-02-15
US34771302P 2002-01-11 2002-01-11
PCT/US2002/004440 WO2002065985A2 (en) 2001-02-15 2002-02-14 Methods of treating diabetes mellitus

Publications (1)

Publication Number Publication Date
DK1409006T3 true DK1409006T3 (da) 2011-06-14

Family

ID=26953561

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02709541.3T DK1409006T3 (da) 2001-02-15 2002-02-14 Monodispergerede blandinger og fremgangsmåder til behandling af diabetes

Country Status (17)

Country Link
US (3) US7060675B2 (da)
EP (1) EP1409006B1 (da)
JP (1) JP4113778B2 (da)
KR (1) KR100896945B1 (da)
AT (1) ATE503490T1 (da)
AU (1) AU2002244020B2 (da)
BR (1) BRPI0207700B8 (da)
CA (1) CA2437940C (da)
CY (1) CY1112034T1 (da)
DE (1) DE60239612D1 (da)
DK (1) DK1409006T3 (da)
MX (1) MXPA03007374A (da)
NO (1) NO327586B1 (da)
NZ (1) NZ527392A (da)
PT (1) PT1409006E (da)
WO (1) WO2002065985A2 (da)
ZA (1) ZA200306332B (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1270012A1 (en) * 2001-06-21 2003-01-02 Pfizer Products Inc. Use of pulmonary administration of insulin for treatment of diabetes
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
SG159387A1 (en) * 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
EP1605895A4 (en) * 2003-03-06 2011-08-24 Emisphere Tech Inc ORAL INSULIN THERAPIES AND PROTOCOL
JP2006519881A (ja) * 2003-03-06 2006-08-31 エミスフィアー テクノロジーズ インコーポレイテッド 経口インスリン治療及びプロトコール
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
KR101152470B1 (ko) * 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
EP2054073B1 (en) * 2006-07-11 2014-11-26 Foresee Pharmaceuticals, Inc. Pharmaceutical compositions for sustained release delivery of peptides
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
AU2008257505B2 (en) * 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
AU2008265973A1 (en) * 2007-06-13 2008-12-24 Wake Forest University Health Sciences Methods of restoration of erectile function
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
KR20100111683A (ko) * 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
MY155612A (en) * 2008-07-14 2015-11-13 Biocon Ltd A method of synthesizing a substantially monodispersed mixture of oligomers
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
CN102227213A (zh) * 2008-11-28 2011-10-26 诺沃—诺迪斯克有限公司 适合于衍生化的胰岛素肽的口服施用的药物组合物
RU2011135730A (ru) 2009-01-28 2013-03-10 Смартселлз, Инк. Кристаллические инсулин-коньюгаты
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
JP2012516339A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 外因的刺激型制御放出物質体およびその使用
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
US20110058558A1 (en) * 2009-09-08 2011-03-10 Electronics And Telecommunications Research Institute Network control device and network control method
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104788556A (zh) * 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556742A (en) * 1896-03-24 Trace-fastener
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US3852353A (en) 1972-12-12 1974-12-03 C Heaphy Oral hypoglycemic aminophenylsulfonyl-hydrocarbylbiguanides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (fr) 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4087390A (en) * 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) * 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS53116315A (en) 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4100117A (en) * 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) * 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) * 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4469681A (en) 1979-07-31 1984-09-04 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US4348387A (en) 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1144743B (it) * 1981-07-09 1986-10-29 Mario Cane Apparecchio infusore di insulina perfezionato
US4582820A (en) 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4698264A (en) 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4602043A (en) * 1983-07-18 1986-07-22 Technology Unlimited Inc. Treatment for hypoglycemia
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4704394A (en) 1984-04-25 1987-11-03 Technology Unlimited, Inc. Treatment for hyperactivity
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US4761287A (en) * 1984-05-03 1988-08-02 Technology Unlimited, Inc. Diabetes control by serotonin
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4622392A (en) 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
CA1339955C (en) 1986-10-14 1998-07-14 Richard Eugene Heiney Process for transforming a human insulin precursor to human insulin
GB8706313D0 (en) 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US5093198A (en) * 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
US4822337A (en) * 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4840341A (en) * 1988-05-09 1989-06-20 Hasegawa Gary K Clip and holder
DK257988D0 (da) * 1988-05-11 1988-05-11 Novo Industri As Nye peptider
JPH01308231A (ja) 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
US5055300A (en) 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
IT1229514B (it) 1989-01-30 1991-09-03 Farmhispania S A A Montme Glicoconiugati anfifilici sintetici per impiego neurologico.
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5108568A (en) 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DD297249A5 (de) 1990-08-07 1992-01-02 Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De Verfahren zur automatischen ueberwachung des aushaertegrades an materialbahnen
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5468727A (en) 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69229779T2 (de) 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
FR2675807B1 (fr) 1991-04-23 1994-07-01 Medgenix Group Sa Conjugue de calcitonine et de polyethylene glycol.
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5205415A (en) * 1991-07-10 1993-04-27 The Standard Commercial Tobacco Co., Inc. Modular classifier
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DK0597007T3 (da) 1991-07-26 1996-11-18 Smithkline Beecham Corp V/O mikroemulsioner
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5693769A (en) 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
ES2133633T3 (es) 1992-01-17 1999-09-16 Alfatec Pharma Gmbh Procedimiento para la produccion de polvos, granulados o peletes que contienen una sustancia activa, con una estructura a base de macromoleculas hidrofilas, y su utilizacion.
GB9212511D0 (en) 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
NZ273285A (en) * 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
JP3775796B2 (ja) 1993-10-06 2006-05-17 ニコックス エス エイ 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
US5889153A (en) * 1994-05-20 1999-03-30 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, method for producing the same and intermediate compound therefor
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1996006632A1 (en) 1994-09-01 1996-03-07 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
JPH10510516A (ja) * 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5606038A (en) * 1995-04-10 1997-02-25 Competitive Technologies, Inc. Amphiphilic polyene macrolide antibiotic compounds
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
ATE455171T1 (de) * 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US5830918A (en) 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
PL191222B1 (pl) 1997-02-05 2006-03-31 Hoffmann La Roche Zastosowanie tetrahydrolipstatyny do wytwarzania doustnego farmaceutycznego preparatu do leczenia cukrzycy typu II
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AR012894A1 (es) * 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
HUP0004169A3 (en) * 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
CA2334859A1 (en) 1998-06-12 1999-12-23 Kings College London Insulin analogue
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
JP2002535287A (ja) 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6900033B2 (en) 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
UY27439A1 (es) 2001-09-07 2003-04-30 Nobex Corp Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途

Also Published As

Publication number Publication date
DE60239612D1 (de) 2011-05-12
US20060293219A1 (en) 2006-12-28
BR0207700A (pt) 2005-07-19
EP1409006B1 (en) 2011-03-30
US7060675B2 (en) 2006-06-13
US7381702B2 (en) 2008-06-03
KR20040043113A (ko) 2004-05-22
PT1409006E (pt) 2011-07-01
EP1409006A2 (en) 2004-04-21
CA2437940A1 (en) 2002-08-29
EP1409006A4 (en) 2005-01-19
NO20033617L (no) 2003-10-15
JP2004527487A (ja) 2004-09-09
MXPA03007374A (es) 2003-12-04
BRPI0207700B1 (pt) 2016-06-07
NO20033617D0 (no) 2003-08-14
BRPI0207700B8 (pt) 2021-05-25
ATE503490T1 (de) 2011-04-15
CA2437940C (en) 2012-07-10
WO2002065985A3 (en) 2004-02-19
US20060100137A1 (en) 2006-05-11
US20030050228A1 (en) 2003-03-13
WO2002065985A2 (en) 2002-08-29
NO327586B1 (no) 2009-08-24
US7423014B2 (en) 2008-09-09
KR100896945B1 (ko) 2009-05-14
AU2002244020B2 (en) 2007-08-16
NZ527392A (en) 2008-01-31
ZA200306332B (en) 2005-07-27
CY1112034T1 (el) 2015-11-04
JP4113778B2 (ja) 2008-07-09

Similar Documents

Publication Publication Date Title
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
NO20003051L (no) Metode for administrering av AspB28-humant insulin
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
NO20053545L (no) Bindingsmidler som inhiberer myostatin.
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DK0514452T3 (da) Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
NO20052348L (no) Behandling av hemoragisk sjokk
YU101102A (sh) Postupci za lečenje reumatskih oboljenja korišćenjem rastvorljivog ctla4 molekula
EA200300560A1 (ru) Улучшенный способ лечения
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
BR0213293A (pt) Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
SE0102147D0 (sv) New methods
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
ATE293972T1 (de) Behandlung von chronischen schmerzen
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
DE60135911D1 (de) vERWENDUNG VON SULODEXIDE ZUR BEHANDLUNG VON DIABETISCHER NEPHROPATHIE